Autopsy report · NCT07027111
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Cause of deathFunding or business
“Business Decision”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year 5 months before it stopped.
- 14 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Nuvig Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- NVG-2089
- Participants
- 14
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.